Ceria Therapeutics
Ceria Therapeutics is dedicated to developing innovative drug products for inflammatory disorders, aiming to eliminate the consequences of inflammation and resolve diseases. They focus on restoring natural healing by boosting the body's innate ability to regulate inflammation, thereby enabling tissues to heal normally. Their mission is to transform lives by addressing acute and chronic inflammatory conditions through first-in-class therapies.
Industries
Nr. of Employees
small (1-50)
Ceria Therapeutics
Aurora, Colorado, United States, North America
Products
RNA-based therapeutics targeting inflammation
Therapeutic product candidates based on RNA modalities intended to block root causes of uncontrolled inflammation across indications including acute respiratory inflammation, acute kidney injury, sepsis, pancreatitis, and inflammatory bowel disease.
Nanoparticle–miRNA conjugate delivered via hydrogel
A formulation concept combining inorganic nanoparticle–miRNA conjugates with photopolymerized zwitterionic hydrogels for sustained localized delivery to accelerate wound healing.
CNP-miR146a
A single modular active pharmaceutical ingredient combining a miR-146a oligomimetic payload with solid cerium oxide nanoparticles to target and turn down NF-kappaB signaling.
CTX-002
An aerosolized formulation of CNP-miR146a delivered via a soft-mist inhaler for acute lung injury and acute respiratory failure.
CTX-001
An intradermal injectable formulation of CNP-miR146a designed for patients with moderate-to-severe diabetic foot ulcers and advanced pressure ulcers.
RNA-based therapeutics targeting inflammation
Therapeutic product candidates based on RNA modalities intended to block root causes of uncontrolled inflammation across indications including acute respiratory inflammation, acute kidney injury, sepsis, pancreatitis, and inflammatory bowel disease.
Nanoparticle–miRNA conjugate delivered via hydrogel
A formulation concept combining inorganic nanoparticle–miRNA conjugates with photopolymerized zwitterionic hydrogels for sustained localized delivery to accelerate wound healing.
CNP-miR146a
A single modular active pharmaceutical ingredient combining a miR-146a oligomimetic payload with solid cerium oxide nanoparticles to target and turn down NF-kappaB signaling.
CTX-002
An aerosolized formulation of CNP-miR146a delivered via a soft-mist inhaler for acute lung injury and acute respiratory failure.
CTX-001
An intradermal injectable formulation of CNP-miR146a designed for patients with moderate-to-severe diabetic foot ulcers and advanced pressure ulcers.
Services
Internal R&D to advance RNA-based and nanoparticle-conjugated therapeutics from concept through preclinical proof-of-concept.
Development of photopolymerized zwitterionic hydrogel systems for sustained local delivery of nanoparticle–miRNA conjugates in wound applications.
Internal R&D to advance RNA-based and nanoparticle-conjugated therapeutics from concept through preclinical proof-of-concept.
Development of photopolymerized zwitterionic hydrogel systems for sustained local delivery of nanoparticle–miRNA conjugates in wound applications.
Expertise Areas
- RNA therapeutics
- Nanoparticle–oligonucleotide conjugation
- Hydrogel-based sustained drug delivery
- Preclinical and translational development
Key Technologies
- miRNA therapeutics
- Nanoparticle conjugation
- Cerium oxide (inorganic) nanoparticles
- Photopolymerized zwitterionic hydrogels
News & Updates
A publication discussing the use of photopolymerized zwitterionic hydrogels with sustained delivery of cerium oxide nanoparticle-miR146a conjugate to accelerate diabetic wound healing.
Ceria Therapeutics received a SBIR grant to develop a new treatment for diabetic foot ulcers.
Ceria Therapeutics received a Department of Defense contract to develop a treatment for acute lung injuries.
A publication discussing the use of photopolymerized zwitterionic hydrogels with sustained delivery of cerium oxide nanoparticle-miR146a conjugate to accelerate diabetic wound healing.
Ceria Therapeutics received a SBIR grant to develop a new treatment for diabetic foot ulcers.
Ceria Therapeutics received a Department of Defense contract to develop a treatment for acute lung injuries.